A 6-month, Open-label, Safety Trial Of Pregabalin In Adolescent Patients With Fibromyalgia
Overview
- Phase
- Phase 4
- Intervention
- pregabalin
- Conditions
- Fibromyalgia
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Enrollment
- 63
- Locations
- 25
- Primary Endpoint
- Change From Baseline in Pain Numeric Rating Scale by Week
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The main purpose of this study is to evaluate the long-term safety of pregabalin in adolescent patients who participated in the previous fibromyalgia study (A0081180) and who wish to recieve open-label pregabalin
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must have met the inclusion criteria for the preceding fibromyalgia Study A0081180, and have received pregabalin/placebo under double-blind conditions.
Exclusion Criteria
- •Patients may not participate in the study if they experienced a serious adverse event during the previous fibromyalgia study A0081180 which was determined to be related to the study medication by the investigator or sponsor.
Arms & Interventions
Pregabalin
Intervention: pregabalin
Outcomes
Primary Outcomes
Change From Baseline in Pain Numeric Rating Scale by Week
Time Frame: Baseline, Weeks 3, 8, 16, 24 and Last Visit.
The weekly pain numeric rating scale (Weekly Pain NRS) consists of an 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores indicate worse pain. Participants chose the number that best described the pain during the last week. Negative change indicates improvement.